Data describing positive therapeutic effects of low-dose GNE-0723, a high-potency GluN2A-subtype selective PAM with favorable pharmacokinetic properties, in in vitro and animal models of DS and Alzheimer’s disease will be briefly reviewed [12]. The gene discussed is GRIN2A; the disease is Dravet syndrome.